Sanofi To Expand Vaccine Manufacturing Facility in France
Sanofi is investing EUR 170 million ($201 million) to expand a vaccine manufacturing site in Val de Reuil, France.
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to expand supply of its quadrivalent influenza vaccine, VaxigripTetra, to up to 70 countries. The vaccine, approved in Europe in June 2016, contains two A strains and two B strains of influenza virus as per World Health Organization recommendation.
Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals and will begin producing vaccines in this new facility in 2022.
This investment is one of several investments Sanofi has made in recent years to improve and expand its vaccine production capacities across France, the US, and Mexico.